期刊文献+

微移植——老年急性髓系白血病治疗新策略 被引量:5

Microtransplantation——new treatment strategy for elderly patients with acute myeloid leukemia
原文传递
导出
摘要 目前老年白血病的界定尚不十分明确,文献报道50-70岁不等,多数学者将年龄≥60岁定义为老年白血病。我国老年白血病以急性髓系白血病(AML)多见,随年龄增长发病率逐渐升高,60-69岁为发病高峰。老年AML具有脏器功能差、化疗后造血恢复慢、耐药率高等生物学特点和临床特征,其诱导缓解率仅40%左右、持续完全缓解(CR)时间〈12个月、中位生存期〈2年。
出处 《临床血液学杂志》 CAS 2014年第3期368-370,共3页 Journal of Clinical Hematology
关键词 白血病 髓系 急性 微移植 治疗 acute myeloid leukemia microtransplantation treatment
  • 相关文献

参考文献11

  • 1ESTEY E. AML in older patients:are we making pro- gress? [J]. Best Praet Res Clin Haematol, 2009,22: 529-536.
  • 2YANADA M, NAOE T. Acute myeloid leukemia in older adults[J]. Int J Hematol, 2012,96 : 186- 193.
  • 3BUCHNER T, BERDEL W E, HAFERLACH C, et al. Age-related risk profile and chemotherapy dose re- sponse in acute myeloid leukemia: a study by the Ger- man Acute Myeloid Leukemia Cooperative Group[J]. J Clin 0ncol,2009,27:61-69.
  • 4艾辉胜,黄晓军,乔振华,王健民,陈宝安,白海,时宝赋,梁英民,孙万军.非清髓异基因造血干细胞移植治疗血液病多中心临床报告[J].中华血液学杂志,2009,30(8):505-508. 被引量:10
  • 5ZEIDAN A M, FORDE P M, SYMONS H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplanta- tion[J]. Biol Blood Marrow Transplant, 2014, 20: 314-318.
  • 6MORRIS E S, MACDONALD K P, HILL G R. Stem cell mobilization with G-CSF analogs: a rational ap- proach to separate GVHD and GVL? [J]. Blood, 2006,107:3430-3435.
  • 7GUO M, HU K X,YU C L,et al. Infusion of HLA mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients[J]. Blood, 2011,117 : 936 - 941.
  • 8GUO M, HU K X, LIU G X, et al. HLA-mismatchedstem-cell microtransplantation as postremission thera- py for acute myeloid leukemia: long-term follow-up [J]. J Clin Oncoi,2012,30:4084-4090.
  • 9魏立,左洪莉,刘铁强,孙雪东,郭梅,刘广贤,孙琪云,乔建辉,王丹红,余长林,胡凯勋,董征,艾辉胜.异基因非清髓造血干细胞移植后WT1特异性T细胞亚群与移植物抗宿主病的关系[J].中华血液学杂志,2011,32(2):89-93. 被引量:1
  • 10DEY B R, MCAFEE S, COLBY C, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allo- geneic stem cell transplantation[J]. Br J Haematol, 2005,128:351-359.

二级参考文献25

  • 1Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies : what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program,2005:384-389.
  • 2Huang CA, Fuchimoto Y, Scheirer-Dolberg R,et al. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest,2000,1:173-181.
  • 3Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood,2005, 105 : 1810-1814.
  • 4Negrin R, Stirb R, Forman S. Bone marrow transplantation in malignant diseaes. In: McArthur JR. Schechter GP. Schrier SL (eds). Hematology. Washington: The American Society of Hematology. Education: Program Book, 1998 : 302-320.
  • 5de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietie stem cell transplantation. Blood, 2004,104:865-872.
  • 6Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol, 2006, 24:444- 453.
  • 7Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of European group for Blood and Marrow Transplantation (EBMT). Leukemia, 2005, 19: 2304-2312.
  • 8Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative and conditioning before hematopoietic cell transplantation from HLA- matched related donors. Blood, 2004, 104:1550-1558.
  • 9Slavin S, Nagler A, Naparstek A ,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantion with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998,91:756-763.
  • 10Storb R. Nonmyeloabalative conditioning regimens for allogeneic stem cell transplantation. 1999 ; Hematology 1999. Washington : The American Society of Hematology Education Program Book,1999: 396-404.

共引文献9

同被引文献35

引证文献5

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部